245P - Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a meta-analysis

Date 28 September 2014
Event ESMO 2014
Session Poster Display session
Topics Complications/Toxicities of Treatment
Presenter Omar Abdel-Rahman
Citation Annals of Oncology (2014) 25 (suppl_4): iv58-iv84. 10.1093/annonc/mdu326
Authors O. Abdel-Rahman, M. Fouad
  • Oncology, Ain Shams university Faculty of medicine, 11361 - Cairo/EG



We performed a systematic review and meta-analysis of the correlation beween cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab.


Eligible studies included phase I, II and III trials of patients with solid tumors on cetuximab; describing events of skin rash and correlating skin rash with overall survival (OS), progression free survival (PFS) and/or overall response rate (ORR).


Our search strategy yielded 409 potentially relevant citations on CETUXIMAB from Pubmed/Medline, CENTRAL Cochrane registry and ASCO meeting library. After exclusion of ineligible studies, a total of 13 clinical trials were considered eligible for the meta-analysis, including 4 phase III trials, 8 phase II trials and one phase I trial. The occurrence of cetuximab-induced rash in patients was highly associated with improvements in PFS (HR = 0.74; 95% CI: 0.63–0.86, P <0.0002), OS (HR = 0.60; 95% CI: 0.47–0.76, P <0.0001), and ORR (RR = 1.51, 95% CI: 1.26–1.81, P <0.00001), as compared to patients without rash. Exploratory subgroup analysis showed no effect of tumor types on the RR of ORR.


Our meta-analysis has demonstrated that CETUXIMAB-induced rash is associated with a significantly increased improved OS, PFS and ORR. cetuximab-induced skin rash may represent a prognostic factor in patients with advanced solid tumors.


All authors have declared no conflicts of interest.